Immunotherapy has become an important strategy in clinical cancer treatment and has attracted much attention, especially for the immune checkpoint blockade (ICB) of PD-1/PD-L1 as a clinically validated treatment for manifold-type terminal cancers1,.2 This evidence concerns the gene CD274 and cancer.